Literature DB >> 28718527

Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study.

V Favilla1, G I Russo1, A Zucchi2, G Siracusa3, S Privitera1, S Cimino1, M Madonia2, T Cai4, G Cavallini5, G Liguori6, G D'Achille7, M Silvani8, G Franco9, P Verze10, A Palmieri10, B Torrisi11, V Mirone10, G Morgia1.   

Abstract

Several intralesional therapeutic protocols have been proposed for the treatment of Peyronie's disease. Among all, hyaluronic acid (HA) and verapamil have been differently tested. We aimed to evaluate the efficacy of intralesional verapamil (ILVI) compared with intralesional HA in patients with early onset of Peyronie's disease (PD). This is a multi-centre prospective double-arm, randomized, double-blinded study comparing ILVI vs. intralesional HA after 12-weeks. Sexually active men, older than 18 years and affected by the acute phase of PD were eligible for this study. Patients have been double-blinded randomly divided into two groups (1 : 1 ratio): Group A received intralesional treatment with Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks, while group B received intralesional treatment with HA (0.8% highly purified sodium salt HA 16 mg/2 mL) weekly for 12 weeks. The primary efficacy outcome was the change from the baseline to the endpoint (12 weeks after therapy) for the penile curvature (degree). The secondary outcome was the change in the plaque size and in the International Index of erectile Function (IIEF-5) score. The difference between post- and pre-treatment plaque size was -1.36 mm (SD ± 1.27) for Group A and -1.80 mm (SD ± 2.47) for Group B (p-value = NS). IIEF-5 increased of 1.46 points (SD ± 2.18) in Group A and 1.78 (SD ± 2.48) in Group B (p-value ± NS). No difference in penile curvature was observed in Group A, while in Group B the penile curvature decreased of 4.60° (SD ± 5.63) from the baseline (p < 0.001) and vs. Group A. According to PGI-I results, we found significant difference as concerning patient global impression of improvement (PGI-I) (4.0 vs. 2.0; p < 0.05). This prospective, double-arm, randomized, double-blinded study comparing ILVI vs. HA as intralesional therapy showed greater efficacy of HA in terms of penile curvature and PGI-I.
© 2017 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  Peyronie's disease; hyaluronic acid; intralesional therapy; verapamil

Mesh:

Substances:

Year:  2017        PMID: 28718527     DOI: 10.1111/andr.12368

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  10 in total

1.  2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature.

Authors:  Anthony J Bella; Jay C Lee; Ethan D Grober; Serge Carrier; Francois Benard; Gerald B Brock
Journal:  Can Urol Assoc J       Date:  2018-02-22       Impact factor: 1.862

Review 2.  Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature.

Authors:  Ayad Yousif; Caleb Natale; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2021-01-08       Impact factor: 3.092

3.  Non-conventional therapies for Peyronie's disease: what is the evidence for efficacy?

Authors:  Ishan Aditya; Jethro C C Kwong; Yonah Krakowsky; Ethan D Grober
Journal:  Transl Androl Urol       Date:  2020-03

4.  Comparison of Intralesional Hyaluronic Acid vs. Verapamil for the Treatment of Acute Phase Peyronie's Disease: A Prospective, Open-Label Non-Randomized Clinical Study.

Authors:  Andrea Cocci; Fabrizio Di Maida; Gianmartin Cito; Pierangelo Verrienti; Nicola Laruccia; Riccardo Campi; Andrea Mari; Marina Di Mauro; Marco Falcone; Giovanni E Cacciamani; Giulio Garaffa; Andrea Minervini; Giorgio Ivan Russo
Journal:  World J Mens Health       Date:  2020-01-20       Impact factor: 5.400

Review 5.  Peyronie's disease - outcomes of collagenase clostridium histolyticum injection: A systematic review.

Authors:  Austin T Mefford; Omer Raheem; Faysal A Yafi; Laith M Alzweri
Journal:  Arab J Urol       Date:  2021-08-16

6.  Intralesional collagenase Clostridium histolyticum for acute phase Peyronie's disease: a single-center, retrospective cohort study.

Authors:  Ming-Yeah Y Hu; John T Sigalos; Dyvon T Walker; Michelle K Li; Dar A Yoffe; Neilufar Modiri; Thomas W Gaither; Alvaro J Santamaria; Keith V Regets; Sriram V Eleswarapu; Jesse N Mills
Journal:  Transl Androl Urol       Date:  2022-08

Review 7.  Molecular Mechanisms and Current Pharmacotherapy of Peyronie's Disease: A Review.

Authors:  Fuxun Zhang; Feng Qin; Jiuhong Yuan
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

8.  Oral Administration and Intralesional Injection of Hyaluronic Acid Versus Intralesional Injection Alone in Peyronie's Disease: Results from a Phase III Study.

Authors:  Tommaso Cai; Daniele Tiscione; Vincenzo Favilla; Marco Puglisi; Fabrizio Palumbo; Alessandro Zucchi; Gianni Malossini; Alessandro Palmieri; Truls E Bjerklund Johansen
Journal:  World J Mens Health       Date:  2020-08-14       Impact factor: 5.400

Review 9.  Medical Management of Peyronie's Disease: Review of the Clinical Evidence.

Authors:  Patrick Teloken; Darren Katz
Journal:  Med Sci (Basel)       Date:  2019-09-18

10.  Clinical use of hyaluronic acid in andrology: A review.

Authors:  Alessandro Zucchi; Fabrizio Ildefonso Scroppo; Paolo Capogrosso; Andrea Salonia; Jacopo Duante; Vittorio Bini; Giovanni Liguori; Riccardo Bartoletti
Journal:  Andrology       Date:  2021-08-02       Impact factor: 4.456

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.